Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
3,5-Di-O-Benzoyl-2-Deoxy-2,2-Difluoro-1-O-Methanesulfonyl-D-Ribofuranose stands as a specialized intermediate, key for the synthesis of advanced pharmaceutical compounds. Each molecule carries a backbone derived from ribofuranose, and chemists swap out hydrogen atoms for two fluorines at the two position, adding strength in metabolic stability. Benzoyl groups line up at the three and five positions, expanding steric bulk, tuning reactivity, and providing some protection through synthesis, while the methanesulfonyl at position one ramps up the capability for nucleophilic substitution reactions. Factory shelves and lab storerooms rarely see this compound outside the circles of high-end pharmaceutical research and process chemistry, since it forms the backbone for certain antiviral, anticancer, or nucleotide-based drug design projects.
End users reach for 3,5-Di-O-Benzoyl-2-Deoxy-2,2-Difluoro-1-O-Methanesulfonyl-D-Ribofuranose most often as a key raw material in active pharmaceutical ingredient production, especially for next-generation nucleoside medication. Once processed, this compound builds up into more complex nucleotide analogs. The transformation process puts this molecule in the spotlight for the manufacture of treatments where fluorinated sugar moieties enhance clinical performance, increase oral bioavailability, and strengthen resistance against enzymatic degradation. Because this kind of chemical sits early in the process, quality matters all the way through—from powder purity to how the crystalline form dissolves in solution.
The structure tells its own story. At its core, a five-membered ribofuranose ring supports substitutions that fundamentally alter the way the molecule acts both in chemical reactors and in living tissues. With benzoyl groups at the 3 and 5 positions, each one giving extra bulk and controlling side reactions, the 2,2-difluoro units block oxidative enzymes, making this molecule valuable for high-potency targets. A methanesulfonyl group on the primary carbon acts as a sounding board for downstream coupling reactions. Chemists navigating drug development rely on this specific arrangement; each fragment of the molecule ties directly to physical and reactive behavior. Spectroscopic data and elemental analysis confirm structure, giving manufacturers confidence for further process development.
3,5-Di-O-Benzoyl-2-Deoxy-2,2-Difluoro-1-O-Methanesulfonyl-D-Ribofuranose comes to market most often as a solid. Its color ranges from white to faintly off-white, with crystalline or sometimes powdery form depending on exact process conditions during formulation. Some suppliers may deliver this chemical in flakes or small pearls—each one composed of the same dense material but different in handling characteristics. Density often stays consistent around 1.4–1.5 g/cm³, allowing accurate measurement for dosing in batch reactors. This density means shipping and storage plans must factor in not only chemical hazard precautions, but also bulk weight and settling characteristics for larger volumes. The solubility profile fits a molecule with both hydrophobic protecting groups and a polar methanesulfonyl arm: slight solubility in common polar organic solvents (acetonitrile, DMSO, DMF), but relatively low water dissolution.
The formula for this compound, C20H16F2O8S, describes a big molecule by pharmaceutical standards. Every atom plays a role in the desired properties: the fluorines installed specifically for enzyme resistance, the oxygen count bumping up polarity, and the sulfur from methanesulfonyl ensuring leaving group behavior in downstream processes. Analytical chemists use this formula for molecular weight confirmation (typically just over 470 g/mol), NMR spectral assignment, and for regulatory tracking throughout the supply chain. The highly specific structure sets it apart, so mass spectrometry and IR spectra become routine in order to confirm purity batch by batch.
Moving chemicals like 3,5-Di-O-Benzoyl-2-Deoxy-2,2-Difluoro-1-O-Methanesulfonyl-D-Ribofuranose requires knowledge of the local and international trade environment. For customs declaration, the HS code usually sits within the range for protected nucleotide intermediates, often 2932 or 2942 series, depending on the classifier recognizing its nucleoside base or functionalized sugar status. Most importing authorities treat it as a regulated pharmaceutical raw material: not a finished drug, but a compound that calls for oversight in terms of environmental impact, worker safety, and transport. Incidents in the logistics chain highlight the need for clear labeling, airtight containment, and documented material data sheets with every shipment.
Experience in the lab has taught me that even non-volatile solids deserve respect. Dust from this compound can irritate eyes, nose, and lungs, and skin contact sometimes prompts mild allergic reactions for sensitized users. Above all, its methanesulfonyl group, while stable in ambient conditions, can react vigorously with certain reducing agents or nucleophiles. Regulatory filings and material data sheets point out moderate environmental toxicity, so proper containment is more than just a legal requirement—it matters for ecosystem health and lab worker safety alike. For raw material warehouses, good practice pairs adsorption spill kits with strictly enforced chemical hygiene plans. Small operators and large manufacturers alike face risks without strong culture around safety data review, protective gear use, and first-aid readiness.
Raw material selection creates a bottleneck, especially for advanced pharmaceutical intermediates like this one. Poor upstream quality translates quickly into downstream loss: imagine a full reactor run ruined by a single impurity from an unreliable supplier, or failed synthesis because of wrongly declared density or solubility. Over the years, I’ve watched the importance of “know your source” move from optional box-checking to a crucial part of business survival in pharma. Reliable sourcing, based on rigorous and ongoing supplier audits, sits side by side with in-house batch testing: those with the most robust systems hit fewer regulatory snags, avoid waste, and get treatments to market with less risk of patient harm.
Pharmaceutical teams need more than paperwork to get transparency and reliability from their chemical suppliers. Electronic batch tracking and blockchain-based ledgers offer clear chain of custody, limiting risk from adulterated materials. Automation at incoming goods inspection—using near-infrared spectroscopy, rapid purity tests, and integrated ERP systems—can spot off-spec batches before they hit production, saving resources and boosting confidence. Cross-training staff on the specifics of this compound helps: every handler and process chemist shares language, hazard knowledge, and procedural discipline. These upgrades, more than regulatory compliance, shift the industry’s baseline toward better security, quality, and environmental stewardship. Working in this field showed me real human cost from overlooked raw materials—it’s not theoretical when a shortage or quality failure delays a lifesaving medication.
Chengguan District, Lanzhou, Gansu, China
